Expected earnings decline due to weak market conditions for Novus's feed-additive methionine
First written in FY2017. 5 of 13 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Novus International, Inc. / Net sales / US$785 million / Profit before income taxes / US$26 million / Net income / US$21 million」
Novus’s results improved from pretax profit of US$0 million and net income of US$4 million in the previous fiscal year to pretax profit of US$26 million and net income of US$21 million in the current fiscal year. - FY2024WorsenedAnnual report
「Novus International, Inc. / Net sales / US$673 million / Loss before income taxes / US$32 million / Net loss / US$29 million」
Novus’s results deteriorated as its modest loss in the previous fiscal year widened, worsening the situation associated with the previously disclosed concern over lower profit due to weak methionine market conditions. - FY2022MitigatedAnnual report
「Novus International, Inc. / Net sales / US$694 million / Profit before income taxes / US$7 million / Net income / US$3 million」
Novus’s results, which had previously deteriorated against a backdrop of weak methionine market conditions and other factors, improved in the current fiscal year to pretax profit of US$7 million and net income of US$3 million. - FY2021WorsenedAnnual report
「Novus International, Inc. / Net sales / US$684 million / Loss before income taxes / US$54 million / Net loss / US$34 million」
Novus’s net loss widened from US$25 million in the previous fiscal year to US$34 million, deteriorating again after the loss reduction seen in the previous fiscal year. - FY2020MitigatedAnnual report
「Ordinary profit was ¥10.312 billion, up 16.0% from the previous fiscal year, due mainly to the reduction in the loss recorded by Novus International, Inc., an equity-method affiliate of the company, compared with the previous fiscal year.」
Novus’s loss narrowed from a net loss of US$105 million in the previous fiscal year to US$25 million in the current fiscal year, and equity-method investment income of ¥1.841 billion was recorded. - FY2020-Q3RestatedAnnual report
「Ordinary profit was ¥4.076 billion, up 4.3% year on year, due mainly to lower profit at Novus International, Inc., an equity-method affiliate of the company, and despite exchange rates remaining at higher yen levels, while net income attributable to owners of the parent was ¥2.844 billion, down 1.1%.」
Novus’s lower profit was cited as a factor reducing ordinary profit during the cumulative third-quarter period. This filing also does not directly identify weak methionine market conditions as the cause of the lower profit. - FY2020-Q2RestatedAnnual report
「Ordinary profit was ¥2.454 billion, down 27.6% year on year, due mainly to the impact of exchange rates remaining at higher yen levels and lower profit at Novus International, Inc., an equity-method affiliate of the company.」
Novus’s lower profit continued to reduce ordinary profit during the cumulative second-quarter period. This filing does not explicitly identify weak methionine market conditions as the cause of the lower profit. - FY2019WorsenedAnnual report
「Novus International, Inc. Net sales US$733 million Profit (loss) before income taxes loss of US$157 million Net income (loss) loss of US$105 million」
Novus’s net income decreased from US$5 million in the previous fiscal year to a net loss of US$105 million in the current fiscal year, while its pretax loss was US$157 million. - FY2019-Q3RestatedAnnual report
「Ordinary profit was ¥3,906 million, down 27.0% year on year, due mainly to lower profit at Novus International, Inc., an equity-method affiliate of the Company. Net income attributable to owners of the parent was ¥2,875 million, down 16.5% year on year.」
Novus’s lower profit continued to reduce ordinary profit during the cumulative third-quarter period, but this filing does not explicitly establish a direct causal relationship with weak methionine market conditions. - FY2019-Q2RestatedAnnual report
「Ordinary profit was ¥3.390 billion, down 12.8% year on year, due mainly to lower profit at Novus International, Inc., an equity-method affiliate of the company. Net income attributable to owners of the parent was ¥2.474 billion, down 4.3% year on year.」
Novus’s lower profit continues to reduce ordinary profit. This filing does not explicitly identify weak methionine market conditions as the cause. - FY2018-Q3RestatedAnnual report
「Ordinary profit was ¥5,348 million, down 14.0% year on year, due mainly to lower profit at Novus International, Inc., an equity-method affiliate of the Company. Net income attributable to owners of the parent was ¥3,442 million, down 42.3% year on year, due mainly to a decrease in extraordinary income.」
Novus’s lower profit, which became an actual result in the previous filing, continued to reduce ordinary profit during the cumulative third-quarter period of the current fiscal year. - FY2018-Q1MaterialisedAnnual report
「Ordinary profit was ¥2,427 million, down 7.5% year on year, due mainly to lower profit at Novus International, Inc., an equity-method affiliate of the Company. Net income attributable to owners of the parent was ¥1,420 million, down 53.5% year on year.」
The decline in Novus’s profit anticipated in the previous filing became an actual factor reducing ordinary profit in the first quarter of the current fiscal year. However, this filing does not explicitly identify weak methionine market conditions as the cause. - FY2017First statedAnnual report
「At Novus, an equity-method affiliate, the company expects lower profit due to weak market conditions for the feed additive methionine.」
The company identified Novus’s weak market conditions for feed additive methionine for the first time as a factor expected to reduce profit going forward.